Vigabatrin is an efficacious new-generation antiepileptic drug, but visual field loss (VFL) has strongly limited its use. A systematic review has established that vigabatrin increases the risk of VFL fourfold, with age and exposure as predicting factors. For infantile spasms, the benefits of vigabatrin seem to outweigh the VFL risk.
- Catherine Chiron
- Olivier Dulac